Myocardial Tissue Engineering by Shimizu, Tatsuya
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Myocardial Tissue Engineering 
Tatsuya Shimizu 
Institute of Advanced Biomedical Engineering & Science 
Tokyo Women’s Medical University 
Japan 
1. Introduction 
Many lives are lost due to heart diseases including myocardial infarction and 
cardiomyopathy. Recent reports have demonstrated that regenerative medicine has 
promising potential for recovering severe heart failure. Regenerative therapies for heart 
failure include cytokine, gene and cell therapy. Because many types of cardiovascular stem 
cells have been identified and their clinical potentials have been demonstrated for the past 
decade, cell injection therapy has most attracted both researchers and clinicians (Wollert 
2008). On the other hand, significant cell loss due to washing out and cell death has become 
problematic in cell injection technique. So, as next generation of regenerative therapy for 
impaired heart, transplantation of myocardial patches fabricated by tissue engineering 
technology are emerging and are clinically applied. Furthermore, several challenges for 
fabricating functional myocardial tissues/organs, which are electrically communicated, 
pulsate synchronously and evoke contraction power, have also started (Zimmermann, Didie 
et al. 2006). These ambitious challenges may lead to reconstruction of malformed hearts and 
become alternative therapy for heart transplantation.  
Heart tissues are composed of high-dense cylindrical cardiomyocytes and fibroblasts with 
abundant vascular network and collagen-based extracellular matrix (ECM). Cardiomyocytes 
pulsate via sodium and calcium ion transient through cell membrane. They are also 
electrically coupled by gap junctions composed of connexion 43 and rapid electrical 
propagation realizes simultaneous beating as a whole. Continuous blood flow supplies 
oxygen and nutrition, and withdraw the waste for high metabolic demand of heart tissues. 
These structure and function produce mechanical contractions as a blood pump. Therefore 
the researchers should take into account high density culture of cardiomyocyte and 
surrounding cells, sufficient micro blood vessel fabrication, cell/ECM orientation and 
proper cell-to-cell coupling for engineering heart tissues/organs.  
Here, previous and current status of cell injection therapy, myocardial patch transplantation 
and pulsatile myocardial tissue fabrication is described with some future views.  
2. Cell injection therapy 
Cell injection therapy for damaged heart has been researched since the early 1990’s. Many 
researchers have demonstrated the therapeutic potential of isolated cell transplantation into 
myocardium using various types of cell sources both in animal models and in some clinical 
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trials (Puceat 2008). The mechanism of myocardial tissue regeneration has not been 
completely cleared, but most researchers have agreed that transplanted cells secrete several 
cytokines which promote neovascularization, prohibit fibrosis, decrease cell death and 
recruit stem cells, leading to heart function improvement. It has been also asserted that 
some of injected cells differentiate into functional cardiomyocytes and may directly 
contribute to heart contraction improvement. Although some differences may exist in 
according to cell types, multifactorial mechanisms seem to relate with myocardial tissue 
regeneration.  
In addition to cell sourcing, different routes are used for cell administration. Systematic 
intravenous infusion is performed through a central or peripheral vein. This method is 
simple and less invasive, however widespread distribution cause low ratio of cell 
engraftment. Most popular approach is intracoronary cell infusion via a balloon-catheter. 
Injected cells are reached directly in the target myocardial region, however, cells have to 
transmigrate across endothelium wall. Intracardiac injection is performed via pericardium 
during open heart surgery and via endocardium by a catheter with a 3-D 
electromechanical mapping system (NOGA mapping system). These methods realize 
relatively targeted delivery, but myocardial damage and arrhythmia induction are 
problematic. Future clarification will be needed to decide which is the best approach for 
cell injection.    
2.1 Skeletal myoblasts 
Skeletal myoblasts were the first cell source to enter the clinical application for heart tissue 
repair. They lie in a quiescent state on the basal membrane of myofibers and have the 
potential to start to proliferate and differentiate into functional skeletal muscle in response 
to muscle damage. They can be isolated autologously and be expanded from a single biopsy. 
In addition, skeketal myoblasts are relatively resistant to ischemia. Menasche and colleagues 
first applied skeletal myoblast injection via epicardium for patients undergoing coronary 
artery bypass grafting (CABG) (Menasche, Hagege et al. 2001). The phase I clinical study 
(MAGIC I) have shown the feasibility of skeletal myoblast implantation, however, increased 
risk of ventricular arrhythmias after the operation. Then, MAGIC II trial was performed to 
clarify the safety and efficacy, in which all patients received preventive medication and an 
implantable cardioverter-defibrillator for rescuing critical ventricular arrhythmias. In result, 
skeletal myoblast injection failed to significantly improve heart function, leading to sample 
size reduction (Menasche, Alfieri et al. 2008). On the other hand, the trial indicated the 
possibility that high dose cell injection might recover left ventricular dilatation. In addition, 
the other clinical trials of catheter-based myoblast implantation via endocardium have 
revealed functional efficacy (Opie and Dib 2006). According to these results, not the 
regenerative potential of myoblasts themselves but the amount of injected cells and delivery 
system may affect the efficacy. Therefore, it seems that skeletal myoblasts should not be 
excluded as a cell source for heart tissue repair. More optimization of cell delivery and 
comparison of cell sources can address these critical issues. 
2.2 Bone marrow-derived cells 
Bone marrow-derived cells are the most used cells in clinical trials for myocardial tissue 
repair (Wollert 2008). The discovery of circulating progenitor cells originated from human 
bone marrow has stimulated research and clinical use of bone marrow-derived cells 
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(Asahara, Murohara et al. 1997). Bone marrow cells contain different stem and progenitor 
cells which will differentiate into various types of cells including endothelial cells, smooth 
muscle cells and cardiomyocytes. Bone marrow mononuclear cells (BMNCs), which can 
be isolated simply by gradient sedimentation after bone marrow aspiration without 
culture expansion, have been clinically injected via coronary artery from the first. BMNCs 
include heterogeneous cell population of monocytes, hematopoietic stem cells and 
endothelial progenitor cells (EPCs). Therefore, some groups have used BMNCs selected 
by surface markers (CD34+, CD133+) and demonstrated more efficacy of their injection. As 
another cell population, mesenchymal stem cells (MSCs) have been researched and 
clinically used. Although, MSCs represent between 0.01 and 0.001% of all nucleated cells in 
bone marrow, they can be readily expanded in culture. MSCs have the potential to 
differentiate into various types of cells and injected MSCs in heart seem to differentiate 
into myocardial composing cells. Recent studies have revealed rare happening of 
cardiomyocyte differentiation, therefore MSCs seem to recover heart function via their 
cytokine secretion and partial differentiation into vascular cells. As a unique feature, 
MSCs have the potential to escape from immune detection due to the direct inflammatory 
inhibition and the lack of cell-surface molecules. This property has realized allogenic 
mesenchymal stem cell transplantation in clinic and has given high impact on cell therapy 
research field.  
Recent randomized controlled trials of bone marrow-derived cell injection revealed overall 
feasibility and safety. However the data has revealed only marginal increases of ejection 
fraction (EF) even in positive studies (0-5%) (Martin-Rendon, Brunskill et al. 2008). For 
establishing more effective bone marrow-derived cell therapy, optimization of cell source, 
cell dose, delivery method and deliver timing will be needed. 
2.3 Adipose-derived stem cells 
In addition to bone marrow-derived MSCs, stem cells isolated from the stroma of adipose 
tissues have represented regenerative potential for heart tissues (Psaltis, Zannettino et al. 
2008). Adipose tissue-derived stem cells (ASCs) display features similar to that of bone 
marrow-derived MSCs and their angiogenic potential have been reported. Some studies 
have also revealed cardiomyocyte differentiation from ASCs. It has not been clarified which 
mesenchymal stem cells are superior to other cell types, however, reatively easy isolation of 
adipose tissue may push the clinical application of ASCs.  
2.4 Cardiac stem cells 
Cardiac stem cells (CSCs) are also possible cell source for myocardial tissue regeneration. 
Two groups first reported CSC existence in 2003 (Beltrami, Barlucchi et al. 2003; Oh, 
Bradfute et al. 2003). Until then, it was common knowledge that heart was a post mitotic 
organ, but those reports accelerated the researches for identifying surface marker of CSCs 
and culturing them. Islet-1, Sca-1 and c-kit have been known as CSC markers. Recently, it 
has been also confirmed that heart has renewal ability at normal state and the annual rate of 
turning over is 1% at the age of 25 (Bergmann, Bhardwaj et al. 2009). Although the ability of 
CSCs may increase after heart injury, newly formed cardyomyocytes are not sufficient for 
replacing damaged muscle tissues. Therefore isolation and expansion of CSCs have been 
extensively examined. Some groups have used a different approach to make cardiospheres 
from biopsied myocardium, which lead to efficient CSC expansion (Lee, White et al. 2011). 
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Clinical trials for injection therapy of autologous CSCs isolated from biopsy sample are now 
on going.  
2.5 Embryonic stem cells 
Although abundant studies demonstrated that MSCs, ASCs and CSCs have the potential of 
cardiomyocyte differentiation regarding gene and protein expression, there are no studies 
clearly showing beating cardiomyocytes differentiated from those stem cells. On the other 
hand, many researchers have confirmed that embryonic stem cells (ESCs) can differentiate 
into beating cardiomyocytes in vitro and implantation of ESC-derived cardiomyocytes 
improves damaged heart function. Several signal pathways for cardiac differentiation have 
been already clarified and various molecules have been reported as its promoters. For 
example, noggin increased cardiac differentiation efficacy via regulation of Bone 
morphogenetic protein (BMP) signalling pathway (Yuasa, Itabashi et al. 2005) and insulin-
like growth-factor-binding protein 4 (IGFBP4) promotes cardiogenesis by inhibitor of 
canonical Wnt signalling (Zhu, Shiojima et al. 2008). In addition, fibloblast growth factor 
(FGF), retinoic acid, ascorbic acid and cyclosporine A have been reported to have the 
potential to enhance cardiac differentiation from ESCs. The important issue as well as 
cardiac differentiation is purification of cardiomyocytes from heterogeneous cell mixture, 
because contamination of immature cells leads to teratoma formation. Although gene-
modified ESCs harboring neomycin resistance gene or green fluorescent protein (GFP) gene 
in the cardiac-specific gene locus are very useful in non-clinical experiments, safe and 
efficient isolation technologies will be needed for clinical application. Culture media control 
focusing on the differences of cell metabolism may be useful for safe cell selection. Moreover 
immune response of the host is another critical issue. Nucler transfer or cell banking is 
possible approach avoiding immunoreaction.  
Electrical communication and simultaneous beating of implanted ESC-derived 
cardiomyocytes should be also requested for improving damaged heart function without 
arrhythmia. In vivo electrophisiological analyses and the transplantation technology for 
synchronization will be essential for clinical application of these cells.  
2.6 Induced pluripotent stem cells 
Induced pluripotent stem cells (iPSCs) also hold great promise for myocardial tissue 
engineering (Vunjak-Novakovic, Tandon et al. 2010). Terminally differentiated cells can be 
reprogrammed to have the same potential as ESCs by introducing 3 or 4 transcriptional 
factor genes. Furthemore none-gene transfer technologies have been developed in the 
world. The superiority of iPSCs to ESCs is autologous cells, which do not cause immune 
response. Cardiac differentiation of human iPSCs has been reported in the same manner 
with ESCs.  
Several critical issues must be clarified for clinical use, but ESCs/iPSCs-derived 
cardiomyocytes should contribute to myocardial tissue engineering in the view point of 
their pulsatile function and scaling-up.  
2.7 Problems of cell injection therapy 
Cell injection therapies for heart failure are now world-widely performed. While moderate 
success of direct cell injection has been observed, the efficacies seem not to reach the level 
that general clinicians think cell therapy a reliable treatment for heart failure. More 
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optimization of cell source, cell preparation process, injection route, injection timing and 
patient population may increase the effectiveness; however one of the essential issues is 
cell delivery methodology. Cell injection therapy has significant difficulties about cell 
retention in the target tissue. The shape, size, and position of the grafted cells are often 
uncontrollable and large amount of the cells are washed-out. Moreover, once retaining 
cells die due to necrosis and apoptosis. Time course quantification with TUNEL assay 
demonstrated that a large number of the grafted cells die within a few days after injection 
in rat models (Zhang, Methot et al. 2001). In the clinical trial using bone marrow-derived 
cells, it has been also demonstrated that only 1-3% of the cells infused via coronary 
arteries could be detected by 3D positron emission tomography (PET) imaging of the 
patient heart. In this study, a large percentage of cells were found in the liver and spleen 
immediately after the procedures (Hofmann, Wollert et al. 2005). To clear the problem of 
cell loss, hydrogel-cell mixture injection has been pursued. Fibrin, collagen and alginate 
hydrogels are now used. Hydrogels with cells are injected as a liquid phase through 
syringe or catheter, then, they are polymerized and fixed in the target tissues (Kofidis, de 
Bruin et al. 2004). In hydrogel-cell mixture injection therapy, local tissue damage due to 
space occupation of hydrogel itself and inflammatory reaction due to hydrogel 
biodegradation are problematic. 
Therefore, more advanced cell delivery systems have been requested to spread the 
regenerative therapy as one of the reliable treatments for heart failure.  
3. Tissue engineering  
Recent advance of tissue engineering technologies have realized the transplantation of 
tissue-engineered construct “myocardial patch” covering over damaged heart surface 
instead of simple cell injection into myocardium. Grafted cells within myocardial patches 
can survive more and secrete more cytokines, resulting in more heart function 
improvement. Furthermore pulsatile myocardial tissues have been successfully engineered 
by using cardiomyocytes as a seeding cell source. These tissues may directly help heart 
contraction and total heart wall replacement may be possible in future. There are several 
contexts of tissue engineering. 
3.1 Scaffold-based tissue engineering 
Most popular technology of tissue engineering is to seed cells into 3-D pre-fabricated 
biodegradable scaffolds which are made from synthetic polymer and biological material. 
Hydrogel formation after mixing cells and scaffold solution is another approach. 
Decellularized tissues have been also used as scaffolds. These scaffolds play as alternatives for 
extra cellular matrix (ECM), therefore, their cell-adhesiveness and porosity affect survived cell 
amount and engineered tissue quality. Scaffold modification can control its biodegradation 
and tissue formation. Growth factor linkage leads to accelerating tissue formation. Now these 
scaffold-based tissue engineering has been widely applied to cardiovascular tissue 
regeneration as well as other tissue repair (Vunjak-Novakovic, Tandon et al. 2010). 
3.2 Cell sheet-based tissue engineering 
In contrast to scaffold-based tissue engineering, our group have developed unique 
technique involving cell sheet stacking to fabricate 3-D tissues (Shimizu, Yamato et al. 2003). 
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Cell sheets are 2-D connecting pure cells without any scaffolds, therefore cell-dense 3-D 
tissues can be fabricated by stacking cell sheets. Cell sheets are harvested from intelligent 
culture surface “temperature-responsive culture surface”, which are covalently grafted with 
temperature-responsive polymer, poly (N-isopropylacrylamide) (PIPAAm) (Okano, Yamada 
et al. 1993). The surfaces are slightly hydrophobic and cell-adhesive at 37˚C, on the other 
hand, the surface changes to hydrophilic and not cell adhesive below 32˚C. Confluently 
cultured cells on the surface can detach as a contiguous cell sheet simply by reducing 
temperature. Furthermore, biological molecules underneath cell sheets are also preserved 
and play a critical role as an adhesive agent during cell sheet stacking. Cell sheet-based 
tissue engineering has been applied for a wide range of regenerative medicine including 
corneal epithelial replacement, heart tissue repair, pneumothorax repair, liver tissue repair 
and so on.  
According to the spread of the concept fabricating 3-D tissues from 2-D confluent cells, 
several other technologies using this concept have emerged. Cell sheet fabrication 
techniques using fibrin coated dishes or nanofibrous polycaprolactone meshes have been 
reported (Shin, Ishii et al. 2004; Itabashi, Miyoshi et al. 2005). Cell sheet-like constructs have 
been also engineered using magnetite nanoparticles (Ito, Hibino et al. 2005). Magnetically 
labelled cells are attached on culture materials by magnetic force and confluent cells are 
harvested as a cell sheet by magnetic force release. Thus, cell sheet-based tissue engineering 
has now spread in the world as scaffold-free tissue engineering. 
4. Myocardial patch transplantation  
Both scaffold-based and cell sheet-based tissue engineering have been used for myocardial 
patch fabrication. Not only cardiomyocytes but also other types of cells have been used for 
creating myocardial patches and some myocardial patches using non-cardiomyocytes have 
been already clinically transplanted over damaged hearts. (Fig. 1.) 
4.1 Scaffold-based mayocardial patch 
In myocardial patch fabrication, synthetic polymer, biological material and decellularized 
tissue have been used as prefabricated scaffolds. Li and colleagues, who were one of the 
pioneer groups of myocardial tissue engineering, first demonstrated that gelatine sponges 
seeded with cardiac cells have therapeutic potentials for cryoinjured rat hearts (Li, Jia et al. 
1999). Leor and colleagues reported that bioengineered heart grafts using porous alginate 
scaffolds attenuated left ventricular dilatation and heart function deterioration in infarction 
model (Leor, Aboulafia-Etzion et al. 2000). Eschenhagen and Zimmermann’s group have 
developed innovative myocardial tissue engineering approach (Zimmermann, 
Schneiderbanger et al. 2002). They have fabricated 3-D tissues by gelling mixture of cardiac 
cells and collagen solution. The constructs induced systolic wall thickening of the left 
ventricle infracted area and improved fractional shortening of damaged hearts in rat 
myocardial infarction model (Zimmermann, Melnychenko et al. 2006). Small intestinal 
submucosa (SIS) has also been used as a scaffold for myocardial patch. MSC-seeded SIS 
improved heart contraction in rabbit infarction model (Tan, Zhi et al. 2009). There have been 
various types of myocardial patches using different scaffolds and different cell sources. 
Although implantable human myocardial patches using beating cardiomyocytes have not 
been established now, clinical trials of collagen-based myocardial patch with bone marrow 
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cells (MAGNUM trial) (Chachques, Trainini et al. 2007) and vicryl mesh-based myocardial 
patches with fibroblasts (Anginera) ((Mirsadraee, Wilcox et al. 2006)) have revealed 





3. Cell sheet-based TE 
Temperature-responsive 
culture surface 








Fig. 1. Tissue engineering (TE) strategies for myocardial patch fabrication 
4.2 Cell sheet-based myocardial patch 
Many types of cell sheets have been reported to improve impaired heart function (Shimizu, 
Sekine et al. 2009). Cell sheets are transplanted onto heart surface directly via open heart 
surgery and cells can be more effectively delivered as thin, but large-area cell-dense grafts 
than isolated cell injection. Scaffold-based myocardial patches are usually transplanted on 
myocardium with suture, on the other hand, cell sheets are transplanted with no suture 
because biological adhesive proteins underneath cell sheets promote the attachment. When 
neonatal rat cardiac cell sheets were transplanted onto infracted rat hearts, grafted 
cardiomyocytes communicated with host myocardium via gap junctions and blood vessels 
formed within the graft, resulting in significant improvement of heart function (Miyagawa, 
Sawa et al. 2005; Sekine, Shimizu et al. 2006).  
Sawa and colleagues have started to use skeletal myoblasts for cell sheet fabrication, because 
myoblasts can be isolated autologously and are relatively resistant to ischemic condition. 
www.intechopen.com
  
Tissue Engineering for Tissue and Organ Regeneration 
 
10 
The recovery of heart function by skeletal myoblast transplantation has been confirmed in 
rat ischemic model, in dilated cardiomyopathy hamster model, in pacing-induced canine 
heart failure model and in pig infarction model (Memon, Sawa et al. 2005; Hata, Matsumiya 
et al. 2006; Kondoh, Sawa et al. 2006; Miyagawa, Saito et al. 2010). Regarding stacking cell 
sheet number, 3-5 layers are optimal and more layering cause primary necrosis of the 
constructs (Sekiya, Matsumiya et al. 2009). They have demonstrated more hematopoietic 
stem cells and less fibrosis in cell sheet transplantation than in isolated cell injection in 
accordance with more expression of stromal-derived factor 1 (SDF-1), hepatocyte growth 
factor (HGF), and vascular endothelial growth factor (VEGF). Based on these results, clinical 
trial of autologous myoblast sheet transplantation for severe heart failure has started and the 
detailed results will appear soon.    
In the same manner with cell injection therapy, MSCs are used as a candidate cell source for 
human implantable cell sheet. Adipose tissue-derived MSCs and menstrual blood-derived 
MSCs have improved damaged heart function in rat infarction model (Miyahara, Nagaya et 
al. 2006; Hida, Nishiyama et al. 2008). MSCs can gradually grow to form a thick stratum 
containing newly formed blood vessels and some cells seem to differentiate into 
cardiomyocytes at least by histological analyses. Further studies will be needed to confirm 
the differentiation into functional beating cardiomyocytes and possibilities to differentiate 
into unexpected cell types. 
As emerging cell source, cell sheets of stem cell antigen 1-positive (Sca-1-positive) CSCs 
ameliorates cardiac dysfunction in mouse infarction model through cardiomyocyte 
differentiation and paracrine mechanisms mediated via soluble vascular cell adhesion 
molecule 1 (VCAM-1)/very late antigen-4 (VLA-4) signaling pathway (Matsuura, Honda et 
al. 2009). In addition, cardiac cell sheets originated from ESCs/iPSCs have been successfully 
fabricated and their transplantation into animal models is now ongoing.  
For enhancing the efficacy of cell sheet transplantation, gene-modified cell sheets have been 
examined. Bcl-2 expressed myoblast sheets prolonged survival, increased production of 
proangiogenic paracrine mediators, and enhanced the therapeutic efficacy (Kitabayashi, 
Siltanen et al. 2010). HGF overexpression in myoblast sheets enhances their angiogenic 
potential in rat chronic heart failure model (Siltanen, Kitabayashi et al. 2011). As another 
concept, cell sheets co-cultured with endothelial cell sources have been transplanted in rat 
infarction models. Transplantation of EPC co-cultured fibroblast sheet improved heart 
function more than only fibroblast sheet implantation or EPC injection (Kobayashi, Shimizu 
et al. 2008). Furthermore, endothelial cell co-culture within cardiomyocyte sheets induced 
more neovascularization and more improvement of cardiac function than only 
cardiomyocyte sheets (Sekine, Shimizu et al. 2008). These studies indicate advanced 
strategies of cell sheet transplantation.      
As mentioned previously, it is considered that the main mechanism of heart function 
improvement is neovascularization, fibrosis inhibition, apoptosis inhibition and stem cell 
recruitment due to various cytokines secreted from grafted cells. In comparison with cell 
injection approach, increase of cell survival within myocardial patches leads to more 
cytokine secretion, then, resulting in more function improvement. In addition to cytokine 
secretion, myocardial patches may have girdling effect and prohibit heart dilatation. 
Therefore, myocardial patch transplantation is quite different cell delivery method from cell 
injection and has more potential to rescue diseased hearts. In the case of myocardial patches 
using beating cardiomyocytes, direct enhancement of contraction power is additionally 
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expected, however, electrical synchronization between host hearts and transplanted patches 
is a critical issue to be clarified. 
5. Engineering plusatile myocardial tisssue 
Beyond myocardial patch fabrication, several research groups have challenged to fabricate 
pulsatile myocardial tissues by their original tissue engineering strategies. Bioengineered 
contractile myocardial tissues may realize new therapeutics for severe heart diseases and be 
useful as alternatives for animal models.    
5.1 Pre-fabricated scaffold-based myocardial tissue fabrication 
The first approach for engineering functional myocardial tissue is seeding cardiomyocytes 
into synthetic or biological 3-D scaffolds. Vunjak-Novakovic and colleagues first reported 
that seeding primary cultured cardiomyocytes onto disc-shaped polyglycolic acid (PGA) 
scaffolds in rotating bioreactor system resulted in spontaneously pulsatile myocardial 
tissues (Papadaki, Bursac et al. 2001). Optimization of cell population, serum concentration 
and scaffold coating improved electrical conduction velocity of engineered constructs. 
Radisc and colleagues seeded rat cardiomyocytes in Matrigel onto collagen sponges and 
stimulated the constructs electrically. The stimulation improved the conductive and 
contractile properties in accordance with increased expression of myosin heavy chain and 
connexion 43. Furthermore, cardiomyocytes in the electrically stimulated constructs were 
more aligned and elongated as same as those in native heart tissue (Radisic, Park et al. 
2007).  
Following these studies, many research groups have started to engineer myocardial tissue in 
vitro by using various types of scaffolds. Scaffold porosity is one of the critical factors for 
pre-fabricated scaffold-based tissue engineering. High porosity increases seeded cell 
number and facilitates mass transport. Surface modyfication is also important for cell 
attachment and survival. Laminin coating improved cardiomyocyte adhesiveness. In 
addition, scaffold elasticity and degradability affect contraction property of engineered 
myocardium. Further studies are ongoing to development appropriate scaffold materials for 
myocardial tissue engineering.  
5.2 Hydrogel-based myocardial tissue fabrication 
The second approach is to form 3-D tissues by gelling of cardiac cell and matrix solution 
mixture. Eschenhagen and Zimmermann have continuously developed this strategy using 
collagen gel and successfully engineered macroscopically beating cardiac tissues 
(Zimmermann and Cesnjevar 2009). First, neonatal rat cardiomyocytes were suspended in 
collagen I solution and the mixture was poured into the mold. After gelling, the constructs 
were unidirectionally stretched with the mechanical devise. They have also realized 
contraction force measurement. Cyclic stretch introduced cell alignment along the stretching 
direction and increased mitochondrial density, leading to native heart-like tissue. The 
contraction force of engineered myocardium was comparative with native heart tissue and 
responded to pharmacological agents properly. Ring-shaped myocardial tissues were also 
fabricated and combined 5 constructs were transplanted onto infarcted rat hearts. 
Interestingly, the constructs synchronized to each other and improved damaged heart 
function. They have also confirmed that co-culture constructs including cardiomyocytes, 
www.intechopen.com
  
Tissue Engineering for Tissue and Organ Regeneration 
 
12 
fibroblasts and endothelial cells were superior to cardiomyocyte rich constructs in 
morphology and function. Recently, they have also started to utilize human cardiomyocytes 
differentiated from ESC/iPSC as cell source and challenged to create human myocardial 
tissues (Zimmermann 2011). In contrast to pre-fabricated scaffold usage, relatively 
homogeneous myocardial tissues are engineered by hydrogel-based approach. Therefore 
collagen gel-based myocardial tissue engineering has now become popular in the world.        
5.3 Cell sheet-based myocardial tissue fabrication 
The third approach is to engineer 3-D pulsatile myocardial tissues by stacking cardiac cell 
sheets. As mentioned previously, 2-D cell sheets can be harvested from temperature-
responsive culture dishes only by lowering temperature and do not include any materials. 3-
D tissues are constructed by layering cell sheets. Because 2-D confluent cells are directly 
stacked without any scaffolds, resulting constructs are cell-dense 3-D tissues. It is well-
known that 2-D confluent cardiomyocytes connect to each other electrically via gap 
junctions resulting in synchronized beating. Cardiac cell sheets harvested from temperature-
responsive culture dishes maintain this synchronized pulsation (Shimizu, Yamato et al. 
2002). For creating 3-D functional heart tissues by layering cardiac cell sheets, morphological 
and electrical communications between cell sheets are critical. Multiple-electrode 
extracellular recording system revealed that double-layer rat cardiac cell sheets coupled 
electrically about one hour after layering and histological analysis showed the existence of 
connexin 43 between two cardiac cell sheets. Adhesive proteins deposited on cell sheet 
surface are considered to promote these rapid electrical communications (Haraguchi, 
Shimizu et al. 2006). Stacked cardiac cell sheets beat synchronously in macroscopic view and 
the constructs transplanted into rat subcutaneous tissues also pulsated continuously at least 
up to one year and eight months after implantation. Morphological analyses showed 
elongated cardiomyocytes, well-differentiated sarcomeres, gap junctions and multiple blood 
vessels, which were characteristic structure of native heart tissue (Shimizu, Yamato et al. 
2002). Long-term observation revealed that their size, conduction velocity, and contractile 
force increased in proportion to the host growth (Shimizu, Sekine et al. 2006). Recently, 
fabrication of cardiac cell sheets using ESC-originated cardiomyocytes have just started and 
human cardiac cell sheets will appear in near future. 
5.4 Fabrication of vascularized myocardial tissue 
One of the major obstacles in myocardial tissue engineering is scaling-up of the constructs. 
Insufficient supply of oxygen and nutrient, and waste accumulation limit their thickness. 
Actually, cells are sparse in the central area, on the other hand, cells are dense in the outer 
surface (100-200μm) area in scaffold-based myocardial tissue engineering. In the case of cell 
sheet-based myocardial tissue engineering, thickness limit is approximately 80μm (3 layers) 
(Shimizu, Sekine et al. 2006). Several approaches have been examined in the point of view 
overcoming diffusion limit. Perfusion of culture media through the constructs using porous 
scaffolds is one possible approach. Media penetration increased cell migration depth and 
improved cell metabolism. However shear stress due to media flow may prohibit tight cell 
attachment on the scaffold material. Media perfusion with oxygen carrier, perfluorocarbon 
(PFC) has been also examined for improving oxygen transport. PFC usage increased cell 
proliferation and improved pulsatile function. Media penetration is useful to some extent, 
however, it becomes more difficult as cell density increases. 
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To overcome this problem, it has been requested to develop new technologies for 
introducing vasculature or vascular-like structure into engineered tissues. Several 
researchers have tried to generate microchannel network within porous 3-D scaffolds by 
microfabrication techniques including CO2 laser ablation. The technology has not reached to 
mimicking native micro capillary network. On the other hand, recent studies have revealed 
that co-cultured endothelial cells within cardiac constructs can spontaneously form 
vascular-like network in vitro and tubular formation has been found in some parts. It has 
been also confirmed that this pre-vascular structure connected to host blood vessels 
immediately after transplantation and the newly developed vessels within the constructs 
were blood-supplied within a few days (Sekiya, Shimizu et al. 2006). We have already 
demonstrated that the tissue thickness of cardiac cell sheets co-cultured with endothelial 
cells were just twice as the thickness of cardiac cell sheets without endothelial cells (Sekine, 
Shimizu et al. 2008). Although endothelial cell co-culture is helpful for accelerating blood 
vessel formation, more scaling-up is still limited due to primary ischemia until sufficient 
vascularization.  
One possible idea for scaling-up is utilizing in vivo vascularization power. Our group has 
reported that triple-layer cardiac cell sheets were repeatedly implanted after waiting enough 
vascular formation within previously implanted tissues. In result, synchronously beating 
thick myocardial tissues with sufficient micro capillaries were successfully fabricated and 
10-times transplantation of triple-layer constructs (totally 30 sheets) formed 1-mm thick, 
pulsatile myocardial tissues. Furthermore, when triple-layer grafts were transplanted 
repeatedly over a surgically connectable artery and vein in leg, the multilayer constructs 
were blood-supplied from the thick artery and vein. The constructs were successfully 
resected with the connectable blood vessels and were ectopically transplanted in neck with 
direct vessel anastomoses (Shimizu, Sekine et al. 2006). Recently several groups have also 
utilized in vivo power for myocardial tissue engineering. Cardiomyocytes, ECM alternatives 
and native blood vessels were packed in the special chamber and incubated in vivo. 
Vascularized heart-like tissues were created in the body (Morritt, Bortolotto et al. 2007; Birla, 
Dhawan et al. 2009). 
Furthemore, next challenge is now in vitro fabrication of vascularized myocardial tissues. 
Kofidis and colleagues have constructed fibrin gel-based myocardial tissues containing rat 
aortas (1-2mm), through which culture media was perfused (Kofidis, Lenz et al. 2003). Cell 
survival and metabolism were improved, however formation of functional blood vessels 
connecting with central aortas were not clear. We are now trying to promote endothelial cell 
tubular formation within in vitro engineered cardiac tissues and to perfuse culture media 
through the newly formed vessels using perfusion bioreactors. Further studies will be 
needed to break through the obstacles for in vitro scaling up.  
5.5 From tissue engineering to organ engineering  
For future organ engineering, some groups have challenged to engineer myocardial 
constructs with pumping function. Ott and colleagues have used decellularized organ as a 
scaffold. They decellularized rat whole hearts and re-seeded cardiac cells into decellularized 
hearts. Heart contraction was recovered and pump function was generated (Ott, Matthiesen 
et al. 2008). Zimmermann’s group developed pouch-like myocardial tissue by their 
technology as previously described and covered heart with pouch-like constructs (Yildirim, 
Naito et al. 2007).  
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Regarding cell sheet technology, myocardial tubes have been fabricated by wrapping rat 
cardiac cell sheets around fibrin tubes and rat resected aortas. The engineered myocardial 
tubes revealed spontaneous, synchronized pulsation and small but significant inner 
pressure changes (about 0.1 mmHg) in vitro (Kubo, Shimizu et al. 2007). On the other hand, 
resected rat aortas wrapped with cardiac cell sheets were micro surgically transplanted in 
place of the abdominal aorta. After 1 month, in vivo myocardial tubes demonstrated 
spontaneous beating and evoked independent blood pressures (about 6 mm Hg). The value 
of in vivo myocardial tubes was much bigger than in vitro myocardial tubes (Sekine, 
Shimizu et al. 2006). Comparing in vitro and in vivo, it was considered that pulsation due to 
host blood flow has induced cardiomyocyte hypertrophy, leading to improvement of 
pumping function. Therefore pulsatile perfusion bioreactors may improve pumping 
function of in vitro engineered myocardial tubes. 
Thus, small size myocardial constructs evoking pumping function have been realized. 
Expansion and selection of cardiomyocytes, and sufficient blood vessel formation for 
scaling-up are now critical issues for organ engineering.   
6. Conclusions 
As the first generation of cardiac regenerative therapy, many clinical trials of cell injection 
therapy have been already performed. The controversial arguments about its effectiveness 
will be settled in next several years. Tissue engineered myocardial patches have now 
emerged as the second generation and previous studies indicate promising potential for 
rescuing damaged heart. As the third generation, tissue-engineered pulsatile myocardial 
tissues should support heart contraction physically. Furthermore, future development of cell 
sourcing and scaling-up technologies may realize “bioengineered hearts”.  
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